A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

Phase 2 Terminated 18 enrolled Hoosier Cancer Research Network Amgen · collab Bayer · collab Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent activity in previously treated advanced breast cancer. This trial will test combined VEGF inhibition with sorafenib and bevacizumab in less heavily pre-treated patients with advanced breast cancer.

Timeline

Start: 2007-10
Primary completion: 2009-03
Completion: 2009-03

Outcome

Outcome not reported

Stopped: “Significant Toxicities Experienced”

Publications

Results Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Invest New Drugs. 2013 Oct;31(5):1307-10. doi: 10.1007/s10637-013-9976-1. Epub 2013 Jun 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Subject	Sorafenib	Small molecule	200 mg	Oral